Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

ClinicalTrials.gov ID: NCT05256134

Public ClinicalTrials.gov record NCT05256134. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of participants for this study is approximately 1200 participants randomized in a 1:1 ratio to receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600 participants randomized to placebo).

Study identification

NCT ID
NCT05256134
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
25 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
60 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 18, 2022
Primary completion
Mar 12, 2023
Completion
Mar 12, 2023
Last update posted
Jun 11, 2025

2022 – 2023

United States locations

U.S. sites
32
U.S. states
15
U.S. cities
31
Facility City State ZIP Site status
Banner Alzheimer?s Institute Phoenix Arizona 85006
Banner Sun Health Research Insitute Sun City Arizona 85351
Banner Alzheimer's Institute Tucson Arizona 85718
California Neuroscience Research Medical Group, Inc Sherman Oaks California 91403
JEM Research LLC Atlantis Florida 33462
Visionary Investigators Network - Neurology Aventura Aventura Florida 33180
Bradenton Research Center Bradenton Florida 34205
Brain Matters Research, Inc. Delray Beach Florida 33445
Neuropsychiatric Research; Center of Southwest Florida Fort Myers Florida 33912
ClinCloud, LLC Maitland Florida 32751
K2 Medical Research, LLC Maitland Florida 32751
Optimus U Corp Miami Florida 33125
Renstar Medical Research Ocala Florida 34470
Charter Research - Winter Park/Orlando Orlando Florida 32803
Progressive Medical Research Port Orange Florida 32127
Alzheimer's Research and Treatment Center Stuart Florida 34997
Charter Research - Lady Lake/The Villages The Villages Florida 32162
Alzheimer?s Research and Treatment Center Wellington Florida 33414
Premiere Research Institute West Palm Beach Florida 33407
Center for Advanced Research & Education Gainesville Georgia 30501
Great Lakes Clinical Trials Chicago Illinois 60640
Via Christi Research Wichita Kansas 67214
Tandem Clinical Research, LLC Marrero Louisiana 70072
Quest Research Institute Farmington Hills Michigan 48334
University of Nebraska Medical Center; Dept of Neurological Sciences Omaha Nebraska 68198-8440
The Cognitive and Research Center of New Jersey Springfield New Jersey 07081
Velocity Clinical Research East Syracuse New York 13057
Alzheimer's Memory Center Matthews North Carolina 28105
Ohio State University; College of Medicine Columbus Ohio 43210
Senior Adults Specialty Research Austin Texas 78757
Kerwin Medical Center Dallas Texas 75231
Re:Cognition Health Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05256134, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 11, 2025 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05256134 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →